Allele-Specific Small Interfering RNA Corrects Aberrant Cellular Phenotype in Keratitis-Ichthyosis-Deafness Syndrome Keratinocytes.
Alleles
Animals
Cell Line
Chimera
Connexin 26
Connexins
/ genetics
Gap Junctions
/ metabolism
Heterografts
Heterozygote
Humans
Keratinocytes
/ physiology
Keratitis
/ genetics
Membrane Potentials
Mice
Mutation, Missense
/ genetics
RNA, Small Interfering
/ genetics
Skin
/ metabolism
Skin Transplantation
Journal
The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
20
02
2019
revised:
16
08
2019
accepted:
17
09
2019
pubmed:
11
11
2019
medline:
7
1
2021
entrez:
10
11
2019
Statut:
ppublish
Résumé
Keratitis-ichthyosis-deafness (KID) syndrome is a severe, untreatable condition characterized by ocular, auditory, and cutaneous abnormalities, with major complications of infection and skin cancer. Most cases of KID syndrome (86%) are caused by a heterozygous missense mutation (c.148G>A, p.D50N) in the GJB2 gene, encoding gap junction protein Cx26, which alters gating properties of Cx26 channels in a dominant manner. We hypothesized that a mutant allele-specific small interfering RNA could rescue the cellular phenotype in patient keratinocytes (KCs). A KID syndrome cell line (KID-KC) was established from primary patient KCs with a heterozygous p.D50N mutation. This cell line displayed impaired gap junction communication and hyperactive hemichannels, confirmed by dye transfer, patch clamp, and neurobiotin uptake assays. A human-murine chimeric skin graft model constructed with KID-KCs mimicked patient skin in vivo, further confirming the validity of these cells as a model. In vitro treatment with allele-specific small interfering RNA led to robust inhibition of the mutant GJB2 allele without altering expression of the wild-type allele. This corrected both gap junction and hemichannel activity. Notably, allele-specific small interfering RNA treatment caused only low-level off-target effects in KID-KCs, as detected by genome-wide RNA sequencing. Our data provide an important proof-of-concept and model system for the potential use of allele-specific small interfering RNA in treating KID syndrome and other dominant genetic conditions.
Identifiants
pubmed: 31705875
pii: S0022-202X(19)33381-0
doi: 10.1016/j.jid.2019.09.022
pmc: PMC7395648
mid: NIHMS1613077
pii:
doi:
Substances chimiques
Connexins
0
GJB2 protein, human
0
RNA, Small Interfering
0
Connexin 26
127120-53-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1035-1044.e7Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NEI NIH HHS
ID : R01 EY013163
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026911
Pays : United States
Organisme : Wellcome Trust
ID : WT104076MA
Pays : United Kingdom
Informations de copyright
Copyright © 2019 UCL GOS Institute of Child Health. Published by Elsevier Inc. All rights reserved.
Références
Physiology (Bethesda). 2013 May;28(3):190-8
pubmed: 23636264
Br J Dermatol. 2007 May;156(5):1015-9
pubmed: 17381453
Nat Rev Drug Discov. 2010 Jan;9(1):57-67
pubmed: 20043028
EMBO Mol Med. 2018 Feb;10(2):239-253
pubmed: 29246969
J Gen Physiol. 2013 Jul;142(1):23-35
pubmed: 23797420
J Am Acad Dermatol. 2013 Jul;69(1):127-34
pubmed: 23384797
J Invest Dermatol. 2015 Apr;135(4):1033-1042
pubmed: 25229253
Am J Hum Genet. 2002 May;70(5):1341-8
pubmed: 11912510
J Invest Dermatol. 2001 Oct;117(4):958-64
pubmed: 11676838
Nat Med. 2006 Mar;12(3):348-53
pubmed: 16491086
J Gen Physiol. 2013 Jul;142(1):3-22
pubmed: 23797419
Front Mol Neurosci. 2017 Sep 22;10:298
pubmed: 29018324
Biomol Ther (Seoul). 2017 May 1;25(3):296-307
pubmed: 28365978
Pediatr Dermatol. 1996 Mar-Apr;13(2):105-13
pubmed: 9122065
J Invest Dermatol. 2016 Mar;136(3):574-583
pubmed: 26777423
J Invest Dermatol. 2016 Jan;136(1):225-235
pubmed: 26763442
Am J Physiol Cell Physiol. 2007 Sep;293(3):C1032-48
pubmed: 17615163
J Invest Dermatol. 2015 May;135(5):1338-1347
pubmed: 25625422
J Struct Biol. 2009 Oct;168(1):168-76
pubmed: 19236918
J Invest Dermatol. 2009 Apr;129(4):870-8
pubmed: 18987669
Mol Biol Cell. 2011 Dec;22(24):4776-86
pubmed: 22031297
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):1957-65
pubmed: 15914609
Exp Dermatol. 2012 Aug;21(8):592-8
pubmed: 22643125
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11975-80
pubmed: 22773805
BMC Bioinformatics. 2014 Jun 17;15:192
pubmed: 24934636
Am J Pathol. 2006 Aug;169(2):416-23
pubmed: 16877344
Biochim Biophys Acta. 2012 Aug;1818(8):2068-75
pubmed: 22155211
J Cell Sci. 2005 Apr 1;118(Pt 7):1505-14
pubmed: 15769851
J Cell Biol. 1995 May;129(3):805-17
pubmed: 7537274
Curr Gene Ther. 2015;15(5):503-10
pubmed: 26264709
Biochem J. 2006 Mar 15;394(Pt 3):527-43
pubmed: 16492141
Mol Ther. 2011 Feb;19(2):408-16
pubmed: 20877344
Mol Ther Nucleic Acids. 2012 Feb 14;1:e11
pubmed: 23344722
J Control Release. 2014 Dec 28;196:355-62
pubmed: 25449884
Dermatol Ther. 2015 Mar-Apr;28(2):89-93
pubmed: 25546246
J Control Release. 2013 Mar 28;166(3):211-9
pubmed: 23313112
FEBS Lett. 2014 Apr 17;588(8):1304-14
pubmed: 24607543
J Invest Dermatol. 2002 Apr;118(4):724-7
pubmed: 11918723
J Biol Chem. 2017 Jun 9;292(23):9721-9732
pubmed: 28428247
FEBS Lett. 2015 Jul 8;589(15):1904-10
pubmed: 26070424